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Outbreaks of Clostridium difficile infections (CDI) with increased
severity, high relapse rate and significant mortality have been
related to the emergence of a new, hypervirulent C. difficile strain
in North America and Europe. This emerging strain is referred to
as PCR ribotype 027 (Type 027). Since 2005, individual countries
have developed surveillance studies about the spread of type 027.
C. difficile Type 027 has been reported in 16 European countries. It
has been responsible for outbreaks in Belgium, Germany, Finland,
France, Ireland, Luxembourg, The Netherlands, Switzerland and the
United Kingdom (England, Wales, Northern Ireland and Scotland).

		

It has also been detected in Austria, Denmark, Sweden, Norway,
Hungary, Poland and Spain. Three countries experienced imported
patients with CDI due to Type 027 who acquired the infection abroad.
The antimicrobial resistance pattern is changing, and outbreaks
due to clindamycin-resistant ermB positive Type 027 strains have
occurred in three European countries. Ongoing epidemiological
surveillance of cases of CDI, with periodic characterisation of the
strains involved, is required to detect clustering of cases in time
and space and to monitor the emergence of new, highly virulent
clones.
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Introduction
Since the emergence of a new virulent strain of Clostridium
difficile characterised as toxinotype III, North American pulsedfield type 1 (NAP1), restriction-endonuclease analysis group type
BI and PCR-ribotype 027 (Type 027), multiple outbreaks have
been reported in North America and Europe [1-9]. The increased
virulence of C. difficile Type 027 is thought to be associated with
a 1 base pair deletion at position 117 of the tcdC gene which
leads to an increased or prolonged production of toxins A and B,
and possibly the production of a binary toxin [1-3]. However, these
virulence factors are not unique for Type 027 and are also present
in other PCR ribotypes.
The first reports of outbreaks of C. difficile infections (CDI) due
to Type 027 came from Canada, and the province of Quebec was
the one affected first and most severely [4]. In the United States,
cases of C. difficile Type 027 infection have been reported from
at least 38 states (http://www.cdc.gov/ncidod/dhqp/id_Cdiff.html),
and surveillance of community-acquired CDI has started [10]. By
2007, C. difficile Type 027 had been detected in 11 European
countries [9]. The present report is an update on the situation in
Europe in 2008.
Surveillance efforts
In 2005, the European Study Group for Clostridium difficile
(ESGCD) performed a two-month surveillance study in 38 hospitals
from 14 European countries [5]. Unfortunately, only hospitalacquired CDI were studied and no precise information on the
severity and outcome was collected. The mean incidence of CDI
was 2.45 +/-1.8 cases per 10,000 patient-days. The distribution
of PCR ribotypes varied among hospitals and countries. Of 322
toxinogenic isolates, 20 (6.2%) belonged to Type 027 and were
reported from Ireland, Belgium and The Netherlands. Patients
infected with Type 027 were more likely to have a more severe
disease, and to have been treated by metronidazole or vancomycin
compared to patients infected by another PCR ribotype.
The European Centre for Disease Prevention and Control (ECDC)
recognised this emerging new disease and undertook several actions
to inform all European Union (EU) Member States. ECDC also
offered support for surveillance studies at national and European
level. Another pan-European surveillance study is presently being
organised, which will collect epidemiological and microbiological
data for one month in a selected number of hospitals from all EU
Member States in order to estimate the incidence of hospitalacquired as well as community-acquired CDI. The results of this
study are expected to be available in 2009.
Austria
In Austria, C. difficile Type 027 was reported once in 2006 in
a British tourist suffering from pseudomembranous colitis. In May
2008, two cases of CDI due to Type 027 were found in patients
who had no travel history in the year before their hospitalisation
[11]. Typing patterns of isolates submitted voluntarily since 2006
demonstrate the occurrence of non-027 clusters of CDI cases in
Austrian hospitals. The largest cluster affected a tertiary teaching
hospital in 2006, where C. difficile PCR ribotype 053 represented
10 of 21 CDI cases. CDI is not a reportable disease in Austria.
Hospital discharge data indicate a significant increase of CDI during
the last years, from 777 cases (54 deaths) in 2003 to 997 cases
(80 deaths) in 2004, 1,453 cases (88 deaths) in 2005 and 2,192
cases (150 deaths) in 2006.
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Belgium
In Belgium, laboratory-based surveillance of CDI clusters
performed by the national reference laboratory at the Université
Catholique de Louvain as well as prospective surveillance of CDI
incidence in acute care hospitals monitored by the Institute for
Public Health were initiated in January 2006. Surveillance of CDI
has become a legal obligation since July 2007. In 2007, 896 C.
difficile isolates were analysed at the reference laboratory.
With 17.6% (158 isolates) Type 027 was the most frequently
found type. Other frequently found types were PCR ribotypes
078 and 031, accounting for 6.3% and 5.6% of these isolates,
respectively. Overall, the mean (median) incidence of CDI was
1.7 (1.6) cases per 1,000 admissions and 2.07 (1.86) cases per
10,000 hospital days. Sixty-eight percent of these cases occurred
more than two days after hospital admission.
Denmark
In April 2006, Statens Serum Institut encouraged the Danish
departments of clinical microbiology to report C. difficile cases on
a continuous basis and to forward isolates for characterisation in
cases of severe disease or in outbreak situations. In a retrospective
survey covering a county in Region South Denmark, a cluster of
eight patients with C. difficile Type 027 was detected. The isolates
were recovered from 22 faecal samples that had been collected
between November 2006 and March 2007. All eight cases were
hospitalised in two hospitals in the region. Subsequently, active
surveillance was initiated in the same region for the period JuneAugust 2007, which resulted in five additional Type 027 cases
among 22 C. difficile isolates tested. Interestingly, all 13 isolates
were resistant to newer fluoroquinolones and cephalosporins, but
susceptible to erythromycin and clindamycin.
Finland
The first case of C. difficile Type 027-associated disease was
detected in Finland in October 2007 [12]. Since then the National
Public Health Institute (Kansanterveyslaitos; KTL) has intensified
surveillance and control of CDI. A few additional cases caused
by Type 027 were detected retrospectively, indicating that this
strain had previously been circulating in Finland. The Finnish
Hospital Infection Programme (SIRO) prepared a protocol for CDI
surveillance to detect severe cases and epidemics caused by C.
difficile. Molecular methods for rapid detection of C. difficile Type
027 were set up at two clinical, university-affiliated laboratories
in Helsinki and Turku, and genotyping methods for molecular
epidemiology of C. difficile were set up at KTL.
During the five-month-period from mid-October 2007 to midMarch 2008, isolates of C. difficile Type 027 were reported from four
of the nine health care districts that had sent the isolates to KTL,
and originated from over 20 different health care facilities – most of
them providing primary or long term care – located in southern and
south-western Finland. Of the 268 isolates, 131 (49%) belonged
to Type 027. The remaining isolates were distributed among more
than 30 different PCR ribotypes.
France
In France, the CDI surveillance is based on the mandatory
notification of severe cases or outbreaks of CDI to local health
departments, regional infection control coordinating centres and
the National Institute for Public Health (Institut de Veille Sanitaire;
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InVS). Laboratories are encouraged to send the isolates from
notified cases to a network of six French reference laboratories
for C. difficile.
In April 2006, the first cluster of C. difficile Type 027 was
reported in Northern France. From January 2006 to December
2007, 214 health care facilities reported at least one severe case
or outbreak of CDI and a total of 1,247 cases. Sixty-four health care
facilities (29 in 2006 and 35 in 2007, with no overlap between
these 64) were affected by Type 027. Most cases originated from
healthcare facilities in the Nord Pas-de-Calais region, but in 2007,
small clusters of C. difficile Type 027 were reported from three
other French regions, Picardie, Rhône-Alpes and Lorraine. Among
the 1,227 isolates (511 in 2006 and 716 in 2007) sent for
typing, 337 (27.5%) were identified as Type 027 (212 in 2006,
i.e. 41.5% of the typed isolates, and 125 in 2007, i.e. 17.4% of
the typed isolates). The large majority of strains were resistant to
erythromycin and moxifloxacin, but susceptible to clindamycin.
However, one hospital in Picardie reported an outbreak associated
with a clindamycin-resistant strain that tested positive for the ermB
gene encoding the macrolide-lincosamide-streptogramin B (MLSB)
phenotype.
Unfortunately, no data are available on the occurrence of other
PCR ribotypes.
Germany
Since October 2007, it is mandatory to report severe cases of
CDI to the local authorities. Patient-based notifications are done
by the physician treating the patient. Severe CDI cases are defined
as cases which necessitate readmission to a healthcare facility
due to the relapse of CDI, admission to an intensive care unit
for treatment of CDI or its complications, surgery (colectomy) for
toxic megacolon, perforation or refractory colitis, or lead to death
within 30 days after diagnosis of CDI, if CDI is either the primary
or a contributive cause to death. This mandatory surveillance was
implemented shortly after the first outbreak of C. difficile Type
027 was detected in the region of Trier, Rhineland-Palatine in
September 2007. To date, five of 16 Federal States (Länder), all
of which are located in the south-west of Germany, have reported
cases of CDI due to Type 027 [13,14].
Hungary (not included in the table)
A recently completed surveillance study in three different parts
of Hungary revealed one isolate of Type 027 among 150 C. difficile
isolates collected. The patient had systemic lupus erythematosus
and developed severe CDI after antibiotic treatment for pneumonia
in a hospital in Budapest.
Ireland
After the first report of C. difficile Type 027 in Ireland in 2007,
this type was identified in six additional healthcare settings [15,16].
To date, more than 100 C. difficile Type 027 isolates from Ireland
have been characterised by toxinotyping and 16-23S PCR ribotyping
[15]. Isolates from two healthcare settings were susceptible to
clindamycin (n=11: MIC90=4 mg/l). However, clindamycin-resistant
Type 027 isolates (n=96, MIC90>256 mg/l) were identified in the
five other healthcare institutions. All clindamycin-resistant Type 27
isolates tested positive for the ermB gene. Multiple locus variable
number tandem repeat (MLVA) typing could clearly differentiate
between clindamycin-resistant and -susceptible isolates from the
same geographical region and sub-grouped them into two distinct

		

clusters, with all isolates from the clindamycin-resistant cluster
being were closely related [16].
CDI has become a notifiable disease in the Republic of Ireland
since May 2008 under ‘acute infectious gastroenteritis’ using
the case definition by ESGCD and ECDC. Only new cases will be
reported, and this will enable data to be collected on the national
level, but not on hospital-level. There are moves to make CDI
notifiable in its own right to enable the collection of enhanced
surveillance data (e.g. on origin and onset of CDI). National
guidelines on surveillance, diagnosis and management of C. difficile
have been published in May 2008 [17].
Luxembourg
During the period between October 2006 (start of CDI surveillance
in Luxembourg) and February 2008, 96 (26%) of 368 submitted
C. difficile strains were PCR ribotyped as Type 027. Type 027 was
the type found most frequently, followed by types 001 and 106, but
confirmation for the latter two is pending. The isolates came from
all 10 hospitals in Luxembourg. The situation is ongoing and the
total number of C. difficile isolates is now exceeding the number
of salmonella and campylobacter isolates.
The median age significantly differed between patients with
Type 027 (74 years) and patients with other ribotypes (59 years)
(p=0.001). The mortality rate of CDI due to Type 027 within one
month and within three months of isolate referral was 14.8% and
21.0%, respectively. In a logistic regression model, one-month
mortality of CDI was significantly associated with age over 70
years (p<0.0001), but not with gender (p=0.66) or PCR ribotype
(p=0.14).
Netherlands
Since October 2005, the Centre for Infectious Disease Control
(CIb) at the National Institute for Public Health and the Environment
(Rijks Instituut voor Volksgezondheid en Milieu; RIVM) and the
reference laboratory for C. difficile at Leiden University Medical
Center have encouraged microbiologists to send C. difficile isolates
from patients with a severe course of CDI, or when an increased
incidence of CDI was noticed. During the surveillance period from
2005 to 2007, Type 027 was reported from an increasing number
of healthcare facilities in an endemic form or in outbreaks. At the
end of 2007, 35 healthcare facilities have been affected, compared
to 22 healthcare facilities until the end of 2006 [8]. During the
surveillance period of 2006/2007, five outbreaks with Type 027
occurred, compared to 11 outbreaks in 2005/2006. One hospital
was affected by an outbreak caused by both Type 027 and Type
017.
Comparison of clinical data of patients with CDI due to Type
027 (n=128) and other types (n=443) showed that CDI due to Type
027 was associated with older age, use of cephalosporins (mainly
second generation) and fluoroquinolones (mainly ciprofloxacin).
Patients with Type 027 CDI had more relapses and a more severe
disease with a higher overall and attributable mortality [8]. C.
difficile Type 027 was significantly more often acquired at a health
care institution. Other frequently isolated PCR ribotypes in The
Netherlands were types 014, 001 and 078.
Norway
In December 2007, the first two cases of CDI due to Type 027
in Norway were reported from a university hospital in Oslo [18].
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Surveillance and infection control measures did not reveal other
Type 027 isolates at this hospital. In February 2008, a third case
of CDI due to Type 027 was detected at a nursing home in Oslo.
Since January 2008, the Department of Infection Prevention in
cooperation with the Institute of Microbiology, both at Rikshospitalet
University Hospital, Oslo, have performed genotypic characterisation
of C. difficile. The most frequently found PCR ribotype is Type 014.
Unfortunately, most medical microbiology laboratories in Norway
do not cultivate C. difficile. As a consequence, the distribution of
PCR ribotypes in Norway remains unknown.
Poland
No systematic CDI surveillance has yet been developed in Poland.
Between 2005 and 2007, a surveillance study was performed in
four hospitals in the Mazovia region. Of 400 C. difficile isolates,
one isolate belonged to Type 027. As determined by E-tests, the
isolate was highly resistant to fluoroquinolones (ciprofloxacin,
gatifloxacin and moxifloxacin, MIC≥32 mg/l) and erythromycin
(MIC≥256 mg/l), but susceptible to clindamycin (MIC=6 mg/l),
metronidazole (MIC=0.38 mg/l) and vancomycin (MIC=0.75 mg/l).
The most frequent PCR ribotype was Type 017, which accounted
for approximately 40% of the C. difficile isolates studied.
Spain
Spain does not have a national surveillance programme to
investigate cases of CDI or an official reference laboratory where
hospitals could send C. difficile isolates for further characterisation.
A surveillance study performed between January and June 2007 at
a 1,750-bed, tertiary care hospital in Madrid revealed two cases of
severe CDI due to Type 027. The index case was a Spanish patient
admitted to the intensive care unit, who was transferred from a
hospital in the United Kingdom. The other patient was a laboratory
technician working with C. difficile isolates, who developed CDI
shortly after antibiotic treatment. In this study, a non-specified PCR
ribotype containing the genes for toxins A and B but not for the
binary toxin, was detected in 103 of 388 typed C. difficile isolates
(26.5%, 81 patients).
Since the C. difficile Type 027 has the binary toxin genes, testing
for the presence of these genes is performed for all C. difficile
isolates. Binary toxin-positive strains are subsequently ribotyped.
In contrast to previous studies performed in this hospital, there was
an increase of non-027 C. difficile containing the genes for toxins A
and B and the genes for the binary toxin (13% of the total number
of isolates studied). The PCR ribotype pattern of the binary toxin
positive isolates probably corresponds to Type 078.
Sweden
Three sporadic ‘historical’ moxifloxacin-susceptible isolates
of C. difficile Type 027 were found among 1,325 isolates
collected between 1997 and 2001 in Sweden. In September
2006, the Swedish Institute for Infectious Disease Control
(Smittskyddsinstitutet; SMI) alerted microbiologists and clinicians
about C. difficile Type 027 and laboratories were encouraged to
send C. difficile isolates to SMI for microbiological characterisation
for patients with a severe course of CDI or when an increased CDI
incidence was noticed.
Since epidemic Type 027 isolates have uniformly been
moxifloxacin-resistant , a systematic screening of C. difficile
isolates for moxifloxacin resistance was initiated during 2007 in
four hospitals in Stockholm. In February 2008, this screening was
extended to include all major hospitals in Sweden. Preliminary
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results indicate only one case of moxifloxacin-resistant Type
027 (found in May 2008), but there is currently no indication of
outbreaks due to C. difficile Type 027. The most frequently PCR
ribotypes isolated in Sweden are Types 012 and 014.
Switzerland
In Switzerland, the first outbreak of C. difficile Type 027 was
observed in a geriatric hospital in Basel in 2006 [19]. The index
case was an 82-year old female patient and the outbreak involved
15 other patients between October 2006 and May 2007. It is
likely that the index patient acquired C. difficile Type 027 during a
hospital stay in a foreign country. The median age of the 16 patients
was 83.5 years (interquartile range: 79-92 years). A severe to
moderate course of CDI was reported in seven (44%) of the patients
and crude mortality was 19% (three deaths). All isolates were highly
resistant to moxifloxacin (MIC>32 mg/l), erythromycin (MIC>256
mg/l) and clindamycin (MIC>256 mg/l). MLVA typing revealed one
cluster of genetically highly related (STRD≤2) clindamycin-resistant
Type 027 isolates which differed from the clindamycin-susceptible
Type 027 control isolates and also from clindamycin-resistant
isolates from Ireland.
United Kingdom (UK)
In England and Wales, mandatory surveillance of CDI in patients
over 65 years has been included in the healthcare-associated
infection surveillance system for acute trusts [20]. This mandatory
surveillance programme is operated by the Health Protection
Agency (HPA) on behalf of the Department of Health. Through
its network of regional laboratories in collaboration with the C.
difficile Ribotyping Network for England (CDRNE) and the Anaerobe
Reference Laboratory (ARL) in Cardiff, the HPA further obtains C.
difficile isolates from symptomatic patients in a structured, but
random sampling scheme. In England, 110 out of 145 hospitals
(76%) investigated between April 2007 and February 2008 showed
the presence of C. difficile Type 027. Of 2,084 C. difficile isolates,
42% were typed as Type 027, 19% as Type 106 and 10% as Type
001. In Wales, 10 out of 16 investigated hospitals showed the
presence of C. difficile Type 027.
In Scotland all diagnostic laboratories have been requested since
September 2006 to submit C. difficile isolates to a UK reference
laboratory in the case of severe CDI or outbreaks. The data are
published quarterly [21]. Additionally, isolates from local research
projects have also been submitted for ribotyping, which means that
some hospitals/regions are over-represented in this collection of
isolates. A total of 20 cases of C. difficile Type 027 were identified
in Scotland in the period from September 2006 to April 2008.
Among these were an outbreak with five cases in one hospital in the
West of Scotland and an outbreak with three cases in a hospital in
the North East of Scotland. In total, Type 027 has been detected
in nine acute care hospitals in five different geographical regions
of Scotland. One case was reported from a nursing home.
Until recently, C. difficile Type 027 was not a common PCR
ribotype in Scotland. With the two recent outbreaks the frequency
of 027 has reached 5.7 %. Since 2006, the most frequent PCR
ribotypes in Scotland have consistently been type 106 (55% of
C. difficile isolates) and type 001 (21%). Four isolates of the new
emerging ribotype 078 have been identified in Scotland as well.
In Northern Ireland, a survey was undertaken between September
and December 2006, and 60 samples (4.0% of the annual total of C.

E U R OS U R V E I L L A N C E Vol . 13 · I ss u es 7– 9 · J ul – Se p 20 08 · w w w. e u ros u rve ill an c e . o rg

		

E U RO S U R V E I L L A N C E Vol . 13 · I ssu es 7– 9 · J ul – Se p 20 08 · w w w. e u ros u rve ill an ce . o rg

5

2005

Jan 2007July 2007

Nov. 2007Febr. 2008

2005-2008

Poland

Spain

Sweden

Switzerland

2006-2007

2006
(sept-dec)

Oct 2006April 2008

Wales

Northern
Ireland

Scotland

5.1

1.7

3.0

50.7

7.3

9.1

44.4

38.1

4.6

16.3

0.5

4.2

82.7

60.7

5.3

5.4

10.4

8.3

Population*
(million
inhabitants,
2006)

total: 261 (2007);
acute care: 45 (2007)

total: 31 trusts
(acute care)

total: 13 trusts
(acute care)

total: 170 trusts
(acute care)

total: 337 (2005);
acute care: 192 (2005)

total: 81 (2003);
acute care: 78 (2003)

total: 788

total: 835 (2005);
acute care: n.a.

total: 70;
acute care: 60 (2000)

total: 193;
acute care: 104

total: n.a.;
acute care: 9 (2004)

total: 179 (2004);
acute care: 53 (2005)

total: 3,359;
acute care: 2,104

total: 2,856 (2005);
acute care: 1,599 (2002)

total: 349;
acute care: n.a.
(20 health care districts)

total: 67 (2003);
acute care: 62 (2000)

total: 215;
acute care: 146

total: 264;
acute care: 183

No. of hospitals*
(2006, if not otherwise
mentioned)

total: 26,463 (2007);
acute care: 14,107 (2007)

total: 6220

total: 13,583 (2006/2007);
acute care: 9,344 (2006/2007)

total: 126,976
(acute care, 2006/2007)

total: 41,196 (2005);
acute care: 27,132 (2005)

total: n.a.;
acute care: 25,492 (2005)

total: 159,671

total: 199,769 (2005); acute
care: 178,074 (2002)

total: 19,193;
acute care: 13,868

total: 80,762 (2003);
acute care: 49,715

total: 2,871 (2004);
acute care: 2,307 (2004)

total: 22,985 (2005);
acute care: 12,094 (2005)

total: 683,484;
acute care: 510,767

total: 443,767(2005);
acute care: 224,247 (2005)

total: 36,659;
acute care: 12,730

total: 20,646 (2004);
acute care: 16,779 2004)

total: 55,158;
acute care: 49,435

total: 63,354;
acute care: 52,894

No. of hospital beds*
(2006, if not otherwise
mentioned)

9 / 18 (50 %)

n.a.

10 / 16 (63%)

110 / 145 (76%)

3 / 10

0/4

1/1

1/4

1/2

35 / 70 (50%)

10 / 10

7 / n.a.

13 / n.a.

64 / 214 (30%)

4 / 9 health care
districts

3/6

32 / 74 (43%)

1 / 43 (2%)

No. of positive
hospitals / No.
of hospitals
investigated for
Type 027 (%)

1

n.a.

n.a.

0

n.a

n.a.

1

10

n.a.

n.a.

1

at least 6

n.a.

n.a.

n.a.

n.a.†

No. of
nursing
homes
positive for
Type 027

20 / 253 (5.7%)

0 / 60

unknown

879 / 2,084 (42%)

26 / 250 (10%)

0 / 238‡

4 / 388

1 / 400 (<1%)

3 / 47 (6%)

285 / 1,553 (18%)

96 / 368 (26%)

n.a.

44 / n.a.

337 / 1,227
(27%)

131 / 268 (49%)

13 / 44 (30%)

158 / 896 (18%)

1 / 1,004 (<1%)

No. of Type 027
isolates / Total
no. of isolates
tested (%)**

unknown

unknown

unknown

unknown

unknown

n.a

4.1%

see text

n.a.

2.3%

n.a.

n.a.

unknown

see text

n.a.

Attributable
mortality of
C. difficile
infections

http://www.hps.scot.nhs.uk/haiic/
sshaip/clostridiumdifficile.aspx

http://www.hpa.org.uk/infections/
topics_az/clostridium_difficile/
default.htm

http://www.rivm.nl/cib/
infectieziekten-A-Z/infectieziekten/
Clostridium_difficile/Clostridium_
difficile_draaiboek.jsp

http://www.ndsc.ie/hpsc/A-Z/
Gastroenteric/CDifficile/

http://www.rki.de >
Infektionskrankheiten A-Z >
Clostridium difficile

http://www.invs.sante.fr/raisin

http://www.
belgianinfectioncontrolsociety.be/

http://webribo.ages.at

Updates available at

* Source: European health for all database (HFA-DB), World Health Organization Regional Office for Europe, Copenhagen, Denmark http://data.euro.who.int/hfadb/, except UK National Statistics, http://www.statistics.gov.uk/.
** Number of C. difficile isolates: may differ from number of patients mentioned in the text.
†n.a.: not available.
‡Total no. isolates screened for moxifloxacin resistance (n=238). PCR ribotyping was only performed on moxifloxacin-resistant isolates (n=60).
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Clostridium difficile Type 027 in 15 European countries (due to differences in surveillance methodology the data cannot be directly compared)

Ta b l e

difficile reports) were ribotyped: the most common ribotypes were
001 (35%), 106 (11.6%) and 078 (8.3%). Ribotype 027 was
not identified in this small sample. The first report of ribotype
027 in Northern Ireland related to a specimen in mid-June 2007.
Since then there has been a large hospital outbreak associated with
ribotype 027 (57 reports to date).
An enhanced ribotyping surveillance programme has recently
been established: 59 specimens were ribotyped, of which 35%
were Type 078, 25% were Type 001 and 8% were Type 014/20.
The sample contained two reports of Type 027 (3%). Compared
with the earlier survey in 2006 there has been a marked increase in
ribotype 078 and a decrease in ribotype 001. Further investigations
are underway to analyse this change in ribotype incidence.
Conclusion
As of June 2008, C. difficile Type 027 has been reported from
healthcare facilities in 16 European countries (Figure, Table).
Among those, nine countries have reported outbreaks and seven
countries have reported only sporadic cases. Because of the lack of
national surveillance programmes in many countries, it is at present
impossible to estimate the incidence of C. difficile Type 027 in
Europe. A new, emerging Type 078 strain, with similar mechanisms
for the hyper-production of toxins as Type 027, is increasingly
reported in Belgium, The Netherlands, Northern Ireland, Scotland,
and possibly Spain.

Figure
Distribution of Clostridium difficile Type 027 by country in Europe*
as of June 2008

The occurrence of outbreaks due to clindamycin-resistant Type
027 isolates in three European countries is worrying. Clindamycin
has been considered as a ‘protective’ antibiotic with regards to
the development of CDI due to Type 027 [8]. However, resistance
to clindamycin may increase the risk of CDI in patients receiving
this agent and its use may be an important factor contributing to
its persistence and spread. In addition, the report of erythromycinsusceptible and clindamycin-susceptible Type 027 isolates in
Germany and Denmark indicates that antimicrobial resistance
patterns are very dynamic and can no longer be used to identify
C. difficile Type 027.
All European countries should now be aware about CDI in
healthcare facilities, and specifically about C. difficile Type 027.
Surveillance studies should be performed with uniform definitions,
as proposed by ECDC [1]. These surveillance studies should not only
focus on C. difficile Type 027, but include all major PCR ribotypes
circulating in Europe since the distribution of these ribotypes varies
greatly among European countries and over time.

References
1.

Kuijper EJ, Coignard B, Tull P; the ESCMID Study Group for Clostridium difficile
(ESGCD); EU Member States and the European Centre for Disease Prevention
and Control (ECDC). Emergence of Clostridium difficile-associated disease in
North America and Europe. Clin Microbiol Infect. 2006;12 Suppl 6:2-18.

2.

McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et
al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J
Med. 2005;353(23):2433-41.

3.

Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A
predominantly clonal multi-institutional outbreak of Clostridium difficileassociated diarrhea with high morbidity and mortality. N Engl J Med.
2005;353(23):2442-9.

4.

Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al.
Clostridium difficile–associated diarrhea in a region of Quebec from 1991
to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466-72.

5.

Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I, et al.
Prospective study of Clostridium difficile-associated disease in Europe with
phenotypic and genotypic characterization of the isolates. Clin Microbiol
Infect. 2007;13(11):1048-57.

6.

Kuijper EJ, van Dissel JT, Wilcox MH. Clostridium difficile: changing epidemiology
and new treatment options. Curr Opin Infect Dis. 2007;20(4):376-83.

7.

Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER,
Kuijper EJ. Characteristics and incidence of Clostridium difficile-associated
disease in The Netherlands, 2005. Clin Microbiol Infect. 2007;13(11):1058-64.

8.

Goorhuis A, Van der Kooi T, Vaessen N, Dekker FW, Van den Berg R, Harmanus
C, et al. Spread and epidemiology of Clostridium difficile polymerase chain
reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis.
2007;45(6):695-703.

9.

Kuijper EJ, Coignard B, Brazier JS, Suetens C, Drudy D, Wiuff C, et al. Update
of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe.
Euro Surveill. 2007;12(6):pii=714. Available from: http://www.eurosurveillance.
org/ViewArticle.aspx?ArticleId=714

10. Centers for Disease Control and Prevention (CDC). Surveillance for communityassociated Clostridium difficile--Connecticut, 2006. MMWR Morb Mortal Wkly
Rep 2008;57(13):340-3.
11. Indra A, Huhulescu S, Hasenberger P, Schmid D, Alfery C, Wuerzner R, et al.
First isolation of Clostridium difficile PCR ribotype 027 in Austria. Euro
Surveill. 2006;11(37):pii=3046. Available from: http://www.eurosurveillance.
org/ViewArticle.aspx?ArticleId=3046
12. Lyytikäinen O, Mentula S, Kononen E, Kotila S, Tarkka E, Anttila VJ. First
isolation of Clostridium difficile PCR ribotype 027 in Finland. Euro Surveill.
2007;12(45):pii=3303. Available from: http://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=3303
Outbreaks due to Type 027

Sporadic cases due to Type 027

* Not all countries have performed surveillance studies to C. difficile type 027
and this figure may underestimate the number of affected countries.

6

13. Kleinkauf N, Weiss B, Jansen A, Eckmanns T, Bornhofen B, Kuehnen E, et
al. Confirmed cases and report of clusters of severe infections due
to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill.
2007;12(46):pii=3307. Available from: http://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=3307

E U R OS U R V E I L L A N C E Vol . 13 · I ss u es 7– 9 · J ul – Se p 20 08 · w w w. e u ros u rve ill an c e . o rg

14. Zaiss NH, Weile J, Ackermann G, Kuijper EJ, Witte W, Nuebel U. A case of
Clostridium difficile-associated disease due to the highly virulent clone
of Clostridium difficile PCR ribotype 027, March 2007 in Germany. Euro
Surveill. 2007;12(46):pii=3306. Available from: http://www.eurosurveillance.
org/ViewArticle.aspx?ArticleId=3306
15. Long S, Fenelon L, Fitzgerald S, Nolan N, Burns K, Hannan M, et al. First
isolation and report of clusters of Clostridium difficile PCR 027 cases in
Ireland. Euro Surveill. 2007;12(17):pii=3183. Available from: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=3183
16. Drudy D, Goorhuis A, Bakker D, Kyne L, van den Berg R, Fanning S, et al.
Clindamycin-resistant clone of Clostridium difficile PCR ribotype 027, Europe.
Emerg Infect Dis. In press 2008.
17. Clostridium difficile Sub-Committee. Surveillance, Diagnosis and Management
of Clostridium difficile – associated disease in Ireland. Dublin: Health
Protection Surveillance Centre; 2008. ISBN 978-0-9551236-3-4. Available from:
http://www.ndsc.ie/hpsc/A-Z/Gastroenteric/Clostridiumdifficile/Publications/
File,2936,en.pdf
18. Ingebretsen A, Hansen G, Harmanus C, Kuijper EJ. First confirmed cases
of Clostridium difficile PCR ribotype 027 in Norway. Euro Surveill.
2008;13(2):pii=8011. Available from: http://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=8011
19. Fenner L, Widmer AF, Stranden A, Conzelmann M, Goorhuis A, Harmanus C, et al.
First cluster of clindamycin-resistant Clostridium difficile PCR-ribotype 027
associated disease in Switzerland. Clin Microbiol Infect. 2008;14(5):514-5.
20. Brazier JS, Patel B, Pearson A. Distribution of Clostridium difficile PCR
ribotype 027 in British hospitals. Euro Surveill. 2007;12(17):pii=3182. Available
from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3182
21. The Health Protection Scotland (HPS) C. difficile Working Group. Quarterly
report on the Surveillance of Clostridium difficile Associated Disease (CDAD)
in Scotland, January 2008 - March 2008. HPS Weekly Report. 2008;42(27).

This article was published on 31 July 2008.
Citation style for this article: Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns
T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert
P, Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Delmée M,
Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M, Åkerlund T, VirolainenJulkunen A, Lyytikäinen O, Kotila S, Ingebretsen A, Smyth B, Rooney P, Poxton IR, Monnet
DL. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008.
Euro Surveill. 2008;13(31):pii=18942. Available online: http://www.eurosurveillance.
org/ViewArticle.aspx?ArticleId=18942

		

E U RO S U R V E I L L A N C E Vol . 13 · I ssu es 7– 9 · J ul – Se p 20 08 · w w w. e u ros u rve ill an ce . o rg

7

